Recent updates on 1,2,3-, 1,2,4-, and 1,3,5-triazine hybrids (2017-present): The anticancer activity, structure-activity relationships, and mechanisms of action.

Dong, Gaoli; Jiang, Yingchun; Zhang, Feng; Zhu, Fengyun; Liu, Junna; Xu, Zhi

Dong, Gaoli; Jiang, Yingchun; Zhang, Feng; Zhu, Fengyun; Liu, Junna; Xu, Zhi.

Afiliação

Dong G; School of Chemistry and Pharmaceutical Engineering, Huanghuai University, Zhumadian, China.
Jiang Y; College of Medicine, Huanghuai University, Zhumadian, China.
Zhang F; School of Chemistry and Pharmaceutical Engineering, Huanghuai University, Zhumadian, China.
Zhu F; College of Biology and Food Engineering, Huanghuai University, Zhumadian, China.
Liu J; Industry Innovation & Research and Development Institute of Zhumadian, Huanghuai University, Zhumadian, China.
Xu Z; Industry Innovation & Research and Development Institute of Zhumadian, Huanghuai University, Zhumadian, China.

Arch Pharm (Weinheim) ; 356(3): e2200479, 2023 Mar.

Article em En | MEDLINE | ID: mdl-36372519

Assuntos

Antineoplásicos; Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos; Neoplasias; Humanos; Relação Estrutura-Atividade; Antineoplásicos/farmacologia; Neoplasias/tratamento farmacológico; Desenho de Fármacos; Triazinas/farmacologia; Estrutura Molecular

Palavras-chave

anticancer; heterofused; hybrid molecules; mechanism of action; structure-activity relationships; triazine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Neoplasias / Antineoplásicos Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google